ANDA 40194, held by Sandoz. Methylprednisolone.
As of Nov 16, 2026, ANDA 40194 (Methylprednisolone), held by Sandoz, was first approved by FDA on Oct 31, 1997, with 11 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 31, 1997 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methylprednisolone4MG · tablet;oral | Methylprednisolone | Rx |
| Apr 10, 2026 | Supplement 29Labeling · Standard review | Approved | None posted |
| Aug 1, 2025 | Supplement 28Labeling · Standard review | Approved | None posted |
| Aug 1, 2025 | Supplement 26Labeling · Standard review | Approved | None posted |
| Aug 1, 2025 | Supplement 21Labeling · Standard review | Approved | None posted |
| Nov 20, 2002 | Supplement 7Manufacturing | Approved | None posted |
| Nov 20, 2002 | Supplement 6Manufacturing | Approved | None posted |
| Oct 12, 2001 | Supplement 5Manufacturing | Approved | None posted |
| Oct 12, 2001 | Supplement 4Manufacturing | Approved | None posted |
| Oct 29, 1999 | Supplement 3Manufacturing | Approved | None posted |
| Jun 23, 1998 | Supplement 2Manufacturing | Approved | None posted |
| Dec 5, 1997 | Supplement 1Manufacturing | Approved | None posted |
| Oct 31, 1997 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters